Fintech, E-Sports, Sports Betting, and E-Commerce, and the Cloud: Global Leaders of Alibaba, Peak Fintech, FansUnite and DraftKings Driving Revenue Growth As Digital Transformation Accelerates

NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) — Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Alibaba Group Holdings (NYSE: BABA), Peak Fintech Group (OTC:PKKFF) (CSE: PKK) and FansUnite (OTC: FUNFF) (CSE: FANS) DraftKings Inc. (NASDAQ: DKNG).

Accelerating digital transformation is the tailwind driving new revenue growth opportunities as leaders leverage the Cloud, and AI in sectors as diverse as sports betting to commercial lending, and shopping. Wall Street Reporter highlights the latest comments from industry thought leaders:

DraftKings Inc. (NASDAQ: DKNG), CEO Jason Robins: “Huge Pent-up Demand for Sports Betting”

“…As sports have started to return, we saw revenue improve sequentially each month in the quarter, with June revenue increasing 20% year-over-year on a pro forma basis. This strong overall results and improvement are due to our product innovation, our entry into new jurisdiction, and pent-up demand for sports betting as Live Sports like Golf, European Soccer, NASCAR and UFC started to return. In the first two weeks of MLBs return, we saw three times the handle compared to the first two weeks of the 2019 MLB season. In the first week of the NHL’s return, our handle is more than twice the handle of first week of 2019 NHL playoff…”

“…We significantly expanded our eSports offering and have seen exponential growth in this category. We added popular Madden simulated games and began to include streaming sports within our app, which has become a very popular feature. In fact, since the return of the NHL, the NBA, and Major League Baseball, users have continued to engage with eSports, which gives us confidence in that product’s future….We believe eSports is going to be a huge category – it’s when not if…we believe ultimately eSports betting will be if not the biggest, certainly one of the biggest categories of sports betting over the long-term.”

DraftKings (NASDAQ: DKNG) Earnings Call Highlights:


https://bit.ly/2Hg4wcV

FansUnite (OTC: FUNFF) (CSE: FANS) “Positioned for Exponential Revenue Growth in iGaming, E-sports, Online Sports Betting”

In a recent presentation at Wall Street Reporter’s NEXT SUPER STOCK livestream, FansUnite (OTC: FUNFF) (CSE: FANS) CEO Scott Burton explained how the company’s latest distribution deal with a online casino games aggregator, sets the stage for exponential revenue growth opportunities. In the next 12 months, FUNFF plans to expand its current line from three games to twelve – while adding multiple aggregators for each game – reaching millions of new online casino customers worldwide. With each game generating as much as $500,000 in revenue per month for FUNFF – per online casino – and the potential to be in hundreds of online casinos – these numbers can quickly add up. Watch FansUnite (OTC: FUNFF) NEXT SUPER STOCK livestream: https://bit.ly/37O1RlX

Nov 5 – FUNFF’s wholly-owned UK Sportsbook McBookie achieves record 433% increase in revenue and 713% increase in gross margin in October 2020 compared to October 2019. Much of the growth was attributed to the unveiling of McBookie’s live casino games and increased activity in sports betting which resulted in $7.3M in total betting volume being placed during the month.

Watch FansUnite (OTC: FUNFF) NEXT SUPER STOCK livestream:


https://bit.ly/37O1RlX

Peak Fintech Group (OTC:PKKFF) (CSE: PKK) CEO Johnson Joseph: “China Fintech Revenues Ready to Explode”

NEXT SUPER STOCK conference presenter Peak Fintech Group (OTC:PKKFF) (CSE: PKK) CEO Johnson Joseph, recently spoke with Wall Street Reporter’s investor audience about PKKFF fast growing China fintech business which connects small-medium business with commercial lending solutions. Joseph explained how Peak Fintech has already gained significant traction, generating over C$7.2 million revenue in Q 2020, and is now ready to start scaling revenues as it enters new markets in coming months.

Watch PKKFF Next Super Stock livestream video:


https://bit.ly/3ku9otb

November 6 – PKKFF hires former People’s Bank of China senior manager, Mr. Wenjun Wu, as a special advisor to assist the Company in various business development capacities and in preparing the Company’s Cubeler Lending Hub platform for China’s upcoming digital currency. Mr. Wu is currently the CEO of Chengfangyun Digital Technology Ltd. (CDT), a Fintech company located in Suzhou that he created to provide products and services designed to help companies, banks and financial institutions conduct transactions in digital yuan. Prior to founding CDT, Mr. Wu was a senior manager at the People’s Bank of China (PBOC), China’s Central Bank, where he worked in the Credit Information Centre and Cross-border RMB Settlement departments while also leading the R&D department of the Central Bank’s Nanjing branch. CDT is currently working closely with the PBOC to promote the use and adoption of the digital yuan in Suzhou.

October 20 – PKKFF signed an exclusive agreement with the parent company of national consumer electronics distributor Beijing Dianjing Company Ltd. (“BDC”) to bring financing solutions to BDC’s 60,000 online retail clients.

BDC is a wholesale distributor of consumer electronics whose online retail clients sell laptops, smartphones and other consumer electronic products on China’s top three e-commerce portals: Tmall, JD.com and Pinduoduo. BDC’s clients, who collectively sell about $50B worth of consumer electronics per year, will be able to have up to 90% of the price of the products they purchase from BDC financed. Peak typically earns service fees ranging from 1% to 3% of the value of the credit amounts it helps facilitate, and this represents a total market opportunity of up to $1.35B in annual revenue potential.

Click here to join NEXT SUPER STOCK livestream:


https://bit.ly/3ku9otb

Alibaba Group Holdings (NYSE: BABA) Daniel Zhang CEO: “Big Growth Opportunities in Cloud and Southeast Asia”

In the latest earnings call, Alibaba CEO Daniel Zhang highlighted Alibaba Cloud and expansion in Southeast Asia as important new growth areas:

Cloud Opportunities: “…The pandemic is accelerating demand for cloud infrastructure and services. According to IDC’s latest report, Alibaba Cloud maintained its position as the largest public cloud service provider in China, which is a testament to Alibaba Cloud’s strengthening market leadership. In the June quarter, our cloud computing revenue grew 59% year-over-year in sectors such as Internet, financial services, consumer retail and public services. Alibaba Cloud not only provides infrastructure as a service but also develops industry-specific technology and business solutions to address real-world application requirements for our customers…the China cloud market is going to be somewhere in the $15 billion to $20 billion total size range, and the U.S. market is about 8x that. So the China market is still at a very early stage…”

Southeast Asia Strategic Growth Priority: “…Southeast Asia market is our strategic priority for Alibaba’s globalization strategy…The pandemic has significant impact on many Southeast Asian countries, and it has converted many consumers into online shoppers. We believe the increasing adoption of online shopping is beneficial for healthy growth of the region’s e-commerce industry over the long term… And I think when we look at our Lazada’s operation, we expect to build a more tech-driven, AI-driven sustainable business. Actually, today, in this market, the competition is very extensive, and the people invest and even certifies the buyers, sellers, even shipping fees and trying to get the short-term growth. But we strongly believe we need to build a long-term, sustainable business and so our advantage is, first is about Alibaba technology infrastructure and especially our experience and know-how and technologies in the AI and in the search and recommendation and the supply and demand match mechanism…”

Alibaba (NYSE: BABA) Q1 2021 Earnings Call Highlights:


https://bit.ly/3dZ8vXT

WALL STREET REPORTER

Wall Street Reporter (Est. 1843) is the leading financial news provider, focused on giving investors direct access to CEO’s of promising, publicly-traded companies, and market experts. www.WallStreetReporter.com

About Wall Street Reporter’s Next Super Stock conference:

Wall Street Reporter’s NEXT SUPER STOCK Live! conference is dedicated to featuring select companies that have near-term catalysts in place which can drive transformational growth (and stock appreciation) in the months ahead. Click here to join next livestream event: https://www.wallstreetreporter.com/next-superstock-online-investor-conference/

CONTACT:

WALL STREET REPORTER

(212) 871-2057 ext 7


www.WallStreetReporter.com



Timken Declares Quarterly Dividend of 29 Cents Per Share

PR Newswire

NORTH CANTON, Ohio, Nov. 13, 2020 /PRNewswire/ — The board of directors of The Timken Company (NYSE: TKR; www.timken.com), a world leader in engineered bearings and power transmission products, today approved a four percent increase to the company’s quarterly cash dividend, raising it to 29 cents per share. The dividend is payable on Dec. 3, 2020, to shareholders of record as of Nov. 24, 2020.

This marks the 394th consecutive quarterly dividend paid on the common shares of the company since The Timken Company joined the New York Stock Exchange in 1922, one of the longest-running dividend records among NYSE-listed companies.


About The Timken Company

The Timken Company (NYSE: TKR; www.timken.com) designs a growing portfolio of engineered bearings and power transmission products. With more than a century of knowledge and innovation, we continuously improve the reliability and efficiency of global machinery and equipment to move the world forward. Timken posted $3.8 billion in sales in 2019 and employs more than 17,000 people globally, operating from 42 countries.

Media Relations:
Scott Schroeder
234.262.6420
[email protected]

Investor Relations:
Neil Frohnapple
234.262.2310
[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/timken-declares-quarterly-dividend-of-29-cents-per-share-301172849.html

SOURCE The Timken Company

National Philanthropy Day: BMO Private Wealth Offers Tips for Preparing Heirs for a Lifetime of Charitable Giving

Canada NewsWire

  • Second volume of the digital magazine explores ways to establish a family culture of stewardship and philanthropy
  • Offers guidance on managing and using this wealth to support the causes important to the family

TORONTO, Nov. 13, 2020 /CNW/ – Anticipating a $1 trillion transfer of wealth over the next decade – the largest 10-year wealth transfer in Canadian history (see “A Sudden Windfall”, BMO Wealth Insights, 2018) – BMO Private Wealth is helping families preserve and advance their family’s legacy by establishing a culture of stewardship and philanthropy for the next generation.

Articles from the second volume of the BMO Wealth Insights magazine explore how families can engage their children in charitable giving and philanthropy. In addition to advice on how to prepare heirs for the responsibilities involved with inheriting wealth, BMO Private Wealth provides guidance for teaching children how to use this wealth to improve the lives of others, while supporting the causes important to their family.

“When discussing successful transfers of wealth, it is important for families to consider the responsibilities involved with inheriting the family legacy and how to build a framework that will advance the family’s philanthropic commitments,” said Marvi Ricker, Vice-President and Director, Philanthropic Advisory Services (Strategic Granting), BMO Private Wealth. “Building an enduring legacy starts with establishing and maintaining a family culture of wealth stewardship and philanthropy. BMO Private Wealth’s team of professionals has the experience and resources to help Canadians and their families identify the causes that align with their values and develop strategies to make a meaningful impact now and for future generations.” 


Tips for teaching children the role of wealth stewardship

Cultivating a lasting culture of wealth stewardship and philanthropy begins with engaging the next generation in charitable giving habits that will define how they will steward their time and wealth. BMO Private Wealth encourages Canadians and their families to consider these suggested strategies when preparing their children and grandchildren for a lifetime of charitable giving:

  • Look for teachable moments: Whether it is a discussion at the dinner table, volunteering at a shelter or attending a granting meeting, there are plenty of opportunities to introduce and explain the value of philanthropy and charity to children of all ages. If possible, try teaching children at an early age that one of the most precious commodities a family can give is their time. Encouraging children to volunteer their time can help build their self-esteem and confidence, while exposing them to their community and its diversity.
  • Create a legacy account: Consider allocating a portion of the household budget towards specific charitable causes by opening a designated bank account or establishing a donor-advised fund. Demonstrating the cumulative potential of small sacrifices and how it can amount to a significant contribution in the future can encourage children to adopt these habits and continue these traditions as they become financially independent.
  • Encourage children to take initiative in the process of family philanthropy: After witnessing the potential of dedicating the family’s time and resources to a cause, children may be interested in choosing a worthwhile initiative of their own. Asking children to research and submit a formal proposal or a presentation on the charities they believe will benefit from their support will enrichen the child’s personal experience and connection to the giving process, as well as encourage future giving.

“Building an enduring culture of wealth stewardship and philanthropy starts with habits. By encouraging family members of all ages to participate in acts of charitable giving and responsible wealth management, these habits will develop into a framework of philanthropic family traditions and values that can be passed down to succeeding generations,” said Lydia Potocnik, Vice-President and National Director, Philanthropic Advisory Services, BMO Private Wealth.

To download a copy of BMO Wealth Insights, please visit https://privatewealth.bmo.com/getimage.asp?content_id=87401

BMO Private Wealth is a brand name for a business group consisting of Bank of Montreal and certain of its affiliates in providing private wealth management products and services. Not all products and services are offered by all legal entities within BMO Private Wealth. Banking services are offered through Bank of Montreal. Investment management, wealth planning, tax planning, philanthropy planning services are offered through BMO Nesbitt Burns Inc. and BMO Private Investment Counsel Inc. Estate, trust, and custodial services are offered through BMO Trust Company. BMO Private Wealth legal entities do not offer tax advice. BMO Trust Company and BMO Bank of Montreal are Members of CDIC. ® Registered trademark of Bank of Montreal, used under license.

® Registered trademark of Bank of Montreal, used under licence.

About BMO Financial Group 
Serving customers for 200 years and counting, BMO is a highly diversified financial services provider – the 8th largest bank, by assets, in North America. With total assets of $974 billion as of July 31, 2020, and a team of diverse and highly engaged employees, BMO provides a broad range of personal and commercial banking, wealth management and investment banking products and services to more than 12 million customers and conducts business through three operating groups: Personal and Commercial Banking, BMO Wealth Management and BMO Capital Markets.

SOURCE BMO Financial Group

CSOL Holding Ltd.’s Invitation to the Presentation of Third Quarter 2020 Financial Results

CSOL Holding Ltd. will announce the results for the third quarter 2020 on Friday, Nov 20, 2020. In connection with the release, a telephone conference will be held at 9:00 a.m. (Lima) as described below.

The presentation will be published at 8:00 a.m. (Lima) and will be available on the Company’s website.

In connection with the earnings release Jorge Ramirez Rubio, CEO, and Andrés Colichón Sas, CFO, will host a conference call presentation and a Q&A session at 9:00 a.m. (Lima).

To participate in the conference call, please use the following numbers:

London, UK Local                                             +0800 028 8438

US/Canada International                                  +1 409 981 0728

Zurich, Switzerland, Local                                +044 580 1733

Oslo, Norway, Local                                         +47 2396 4173

Colombia, National Free Phone                         +01 800 518 5094

Chile, National Free Phone                               +56 800 914 686

Peru, National Free Phone                               +51 0800 71470

Participants will be asked for their name and conference ID.

The Camposol conference ID is: 5585231

Audio access for the meeting is available by dialing the above-mentioned numbers.

To access the presentation webcast in connection with the conference call, please use:



https://edge.media-server.com/mmc/p/bvrphfz2

Participants are advised to log on to the service and check their configuration well ahead of the telephone conference commencement.

For further information, please contact:

Andrés Colichón Sas, CFO



[email protected]

 Milagritos Olivero, Controller



[email protected]

Phone: +511 621 0800 Ext.: 7171

  
About CAMPOSOL

CAMPOSOL is a vertically integrated producer of branded fresh and healthy food that offers high quality, healthy and fresh food to consumers around the world, based on a sustainable management model. CAMPOSOL’s portfolio includes superfoods like blueberries, avocados, mandarins, among others.  Additionally, our international commercial platform is responsible for the commercialization of the products of these two units, with offices in the US, The Netherlands, and China.

CAMPOSOL guarantees the full traceability of its products and is committed to supporting sustainable development through social and environmental responsibility policies and projects intended to increase the shared-value for all its stakeholders. On the strength of this value proposition, CAMPOSOL’s commercial offices have established long-term relationships with the top worldwide supermarket chains and service them directly.

CAMPOSOL is also an active member of the Global Compact since 2008. It presents annual Sustainability Reports aligned to the GRI Methodology and has achieved the following international certifications: BSCI, Global Gap, IFS, HACCP, and BRC among others.

To learn more about CAMPOSOL please visit: www.camposol.com.pe



U.S. Physical Therapy to Present at the Jefferies Virtual London Healthcare Conference

U.S. Physical Therapy to Present at the Jefferies Virtual London Healthcare Conference

HOUSTON–(BUSINESS WIRE)–
U.S. Physical Therapy, Inc. (NYSE: USPH), a national operator of outpatient physical therapy clinics (the “Company”), today announced that its Chief Executive Officer, Chris Reading, and Chief Financial Officer, Carey Hendrickson, will participate at the Jefferies Virtual London Healthcare Conference on Tuesday, November 17, 2020. The presentation will cover an overview of the Company.

A copy of the presentation is posted on the Company’s website at www.usph.com.

About U.S. Physical Therapy, Inc.

Founded in 1990, U.S. Physical Therapy, Inc. operates 548 outpatient physical therapy clinics in 39 states. The Company’s clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. In addition to owning and operating clinics, the Company manages 38 physical therapy facilities for unaffiliated third parties, including hospitals and physician groups. The Company also has an industrial injury prevention business which provides onsite services for clients’ employees including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments.

More information about U.S. Physical Therapy, Inc. is available at www.usph.com. The information included on that website is not incorporated into this press release.

U.S. Physical Therapy, Inc.

Carey Hendrickson, Chief Financial Officer

Chris Reading, Chief Executive Officer

(713) 297-7000

Three Part Advisors

Joe Noyons

(817) 778-8424

KEYWORDS: Europe United States United Kingdom North America Texas

INDUSTRY KEYWORDS: General Health Other Health Health Fitness & Nutrition Physical Therapy

MEDIA:

Logo
Logo

CLSN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Celsion CorporationShareholders With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: December 28, 2020

CLSN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Celsion CorporationShareholders With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: December 28, 2020

NEW YORK–(BUSINESS WIRE)–
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against of Celsion Corporation (“Celsion” or “the Company”) (NASDAQ: CLSN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Celsion securities between November 2, 2015 to July 10, 2020, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/clsn.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) defendants had significantly overstated the efficacy of ThermoDox; (2) the foregoing significantly diminished the approval and commercialization prospects for ThermoDox; and (3) as a result, the Company’s public statements were materially false and misleading at all relevant times.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/clsn or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Celsion you have until December 28, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz

212-697-6484 | [email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo

DEADLINE ALERT for ICPT, HPQ, and NVCN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, Nov. 13, 2020 (GLOBE NEWSWIRE) — The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion.

Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected].

Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)
Class Period:   September 28, 2019 – October 7, 2020
Lead Plaintiff Deadline: January 4, 2021

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Defendants downplayed the true scope and severity of safety concerns associated with Ocaliva’s use in treating PBC; (2) the foregoing increased the likelihood of an FDA investigation into Ocaliva’s development, thereby jeopardizing Ocaliva’s continued marketability and the sustainability of its sales; (3) any purported benefits associated with OCA’s efficacy in treating NASH were outweighed by the risks of its use; (4) as a result, the FDA was unlikely to approve the Company’s NDA for OCA in treating patients with liver fibrosis due to NASH; and (5) as a result of all the foregoing, the Company’s public statements were materially false and misleading at all relevant times.

HP Inc. (NYSE: HPQ)
Class Period: November 6, 2015 – June 21, 2016
Lead Plaintiff Deadline: January 4, 2021

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose: (1) that HP’s channel inventory management and sales practices resulted in the sale of supplies to customers that did not need or want the product in order to artificially increase revenues and profits; (2) that HP’s channel inventory management and sales practices resulted in the sale of supplies to customers outside of designated regions at unsustainable discounts in order to artificially increase revenues and profits; (3) that HP’s channel inventory management and sales practices resulted in the sale of supplies at steep discounts to customers to encourage those customers to sell the supplies further down the supply channel, out of HP’s inventory management metrics; and (4) that, as a result of the foregoing, defendants’ statements about the Company’s business condition and prospects were materially false and misleading when made.

Neovasc
Inc. (NASDAQ: NVCN)
Class Period: November 1, 2019 – October 27, 2020
Lead Plaintiff Deadline: January 5, 2021

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the results of COSIRA, Neovasc’s clinical study for the Reducer, contained imbalances in missing information present in the control group versus the treatment group, including significant missing information for secondary endpoints but none for the primary endpoint; (2) that the imbalance in missing information indicated that control subjects were aware of their treatment assignment (not blinded) and less inclined to participate in additional data collection; (3) that blinding is critical when studying a placebo-responsive condition such as angina; (4) that the lack of blinding assessment made the primary endpoint difficult to interpret; (5) that, as a result of the foregoing, the FDA was reasonably likely to require additional premarket clinical data; (6) that, as a result, the Company’s PMA for Reducer was unlikely to be approved without additional clinical data; and (7) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [email protected], or visit our website at www.frankcruzlaw.com.   If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
[email protected]
www.frankcruzlaw.com



ACB STOCK DEADLINE: Zhang Investor Law Reminds Investors With Losses of Deadline in Securities Class Action Lawsuit Against Aurora Cannabis Inc. – ACB

NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) — Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court before the December 1, 2020 DEADLINE. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. 

To join the class action, go to http://zhanginvestorlaw.com/join-action-form/?slug=aurora-cannabis-inc&id=2437 or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email [email protected] for information on the class action.

如果您想加入这个集体诉讼案,请在这里提交您的信息。http://zhanginvestorlaw.com/join-action-form/?slug=aurora-cannabis-inc&id=2437

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: Aurora had significantly overpaid for previous acquisitions and experienced degradation in certain assets, including its production facilities and inventory; the Company’s purported “business transformation plan” and cost reset failed to mitigate the foregoing issues; accordingly, it was foreseeable that the Company would record significant goodwill and asset impairment charges; and as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Lead plaintiff status is not required to seek compensation.  You may retain counsel of your choice.  You may remain an absent class member and take no action at this time.

Zhang Investor Law represents investors worldwide. Attorney Advertising. Prior results do not guarantee similar outcomes.

Zhang Investor Law P.C.
99 Wall Street, Suite 232
New York, New York 10005
[email protected]
tel: (800) 991-3756



ALYI Publishes $100 Million ICO Update From Finance Partner RevoltTOKEN

PR Newswire

DALLAS, Nov. 13, 2020 /PRNewswire/ — Alternet Systems, Inc. (USOTC: ALYI) today announced an update released from their financing partner, RevoltTOKEN.  The update from RevoltTOKEN CEO, Henryk Dabrowski, is included below:

RevoltTOKEN ICO Update

The response to the RevoltTOKEN ICO has been tremendous. We are here at RevoltTOKEN are humbled by the number of people contacting us ready to purchase Tokens. We are also encouraged by the response and in reaction to the response, confident that RevoltTOKEN will meet or exceed its $100 million funding objectives.

We are making steady progress on the necessary preparations for the ICO.  We are also trying to meet the eager market response by moving as quickly through the necessary preparations as possible.

We have previously announced that RevoltTOKEN is domiciling in Bermuda.  Cryptocurrency is a relatively new financing tool.  We have selected a sound technology platform, Ethereum, and we equally think it is important to prudently select a legal domain.

Bermuda is a globally respected business venue with a well-established and efficiently operating legal environment governing business transactions.  Bermuda has elected to take a leadership role in facilitating a cryptocurrency business environment with a standard of integrity that supports investor confidence.

As eager as we are to quickly launch the ICO, are eagerness is balanced by our prudence in carefully insuring a sound regulatory approach into an environment with only a short history of rules and regulations.

We are confident our internal investment resources can satisfy ALYI’s intermediate requirements pending the ICO. If necessary, we are willing to increase our existing interim investment commitments.

In Bermuda’s defense, since we have engaged to domicile and register as a cryptocurrency, Bermuda, like everyone, has had to deal with the restrictions of operating in a COVID environment in addition to dealing with a hurricane coming ashore followed by another near miss.  So, in addition to carefully managing a new financing tool, Bermuda is doing so in the face of some rather notable distractions.

In an effort to exercise the greatest prudence within the new cryptocurrency regulatory environment, RevoltTOKEN is currently exploring and intends to engage more than one registration venue. In addition to registering as a cryptocurrency in Bermuda, RevoltTOKEN intends to register in additional regulatory domains. 

The public trading of stocks has 400 years of history to draw on for regulatory standards.  Cryptocurrencies barely have a 10-year history since inception.  We anticipate a set of universal regulatory standards for cryptocurrencies someday similar to the universal standard for stocks.  At the moment, there is not much of a body of any rules and standards and different legal domains are developing different standards. Also, keep in mind, a larger number of cryptocurrencies trade today without being registered or licensed in any domain.

At RevoltTOKEN we think it is worthwhile to register in multiple domains in an effort to bridge the lack of a universal standard.

We look forward to the ultimate launch of the RevoltTOKEN ICO and working diligently to get there at the right time with the right amount of structure. We will continue to keep you posted on our progress.

For more information and to stay up to date on RevoltTOKEN’s latest developments, please visit www.revolttoken.com.

For more information and to stay up to date on ALYI’s latest developments, please visit www.alternetsystemsinc.com.

Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Alternet Systems, Inc. Contact:
Randell Torno
[email protected]
+1-800-713-0297

Cision View original content:http://www.prnewswire.com/news-releases/alyi-publishes-100-million-ico-update-from-finance-partner-revolttoken-301172847.html

SOURCE Alternet Systems, Inc.

SunLink Health Systems, Inc. Announces Fiscal 2021 First Quarter Results and COVID-19 Update

SunLink Health Systems, Inc. Announces Fiscal 2021 First Quarter Results and COVID-19 Update

ATLANTA–(BUSINESS WIRE)–
SunLink Health Systems, Inc. (NYSE American: SSY) today announced a loss from continuing operations of $291,000 (a loss of $0.04 per fully diluted share) for its first fiscal quarter ended September 30, 2020 compared to a loss of $143,000, (a loss of $0.02 per fully diluted share) for the quarter ended September 30, 2019. Net loss for the quarter ended September 30, 2020 was $340,000 (a loss of $0.05 per fully diluted share) compared to a net loss of $261,000 ($0.04 per fully diluted share) for the quarter ended September 30, 2019.

Consolidated net revenues from continuing operations for the quarters ended September 30, 2020 and 2019 were $10,422,000 and $11,652,000, respectively, a decrease of 10.6% in the current fiscal year’s first quarter compared to the comparable quarter of the prior fiscal year. Net revenues decreased in the current fiscal quarter primarily due to decreased hospital and nursing home net revenues and decreased Pharmacy segment revenues as a result of decreased sales in all product categories primarily due to the COVID-19 pandemic.

SunLink reported an operating loss for the quarter ended September 30, 2020 of $323,000 compared to an operating loss for the quarter ended September 30, 2019 of $220,000.

Loss from discontinued operations was $49,000 (or a loss of $0.01 per fully diluted share) for the quarter ended September 30, 2020 compared to a loss from discontinued operations of $118,000 ($0.02 per fully diluted share) for the quarter ended September 30, 2019.

COVID-19 Pandemic

A novel strain of coronavirus (“COVID-19”) was declared a global pandemic by the World Health Organization on March 11, 2020. We have been monitoring the COVID-19 pandemic and its impact on our operations, and we have taken significant steps intended to minimize the risk to our employees and patients. Certain employees have been working remotely, but we believe these remote work arrangements have not materially affected our ability to maintain critical business operations, which are being conducted substantially in accordance with our understanding of applicable government health and safety protocols and guidance issued in response to the COVID-19 pandemic, although such protocols and guidance are very recent, rapidly changing and at times, unclear. Nevertheless, as in many healthcare environments, we have experienced COVID-19 illness, including deaths, and some employees have tested positive and were placed on leave or in quarantine.

In our Healthcare businesses, we have experienced material reductions in demand and net revenues due to the COVID-19 outbreak. There appears to be minimal current demand for nursing home admissions, and clinic visits and hospital services have substantially decreased as well in part due to the abrupt retirement of one physician and reduced capacity of other physicians and providers, all as a result of the effects of the pandemic. The availability and cost of medical supplies have adversely affected our Healthcare businesses, especially with respect to access to personal protective equipment, cleaning supplies and COVID-19 testing materials. We continue to monitor supplies and seek additional sources of many supply items. A reduction in the availability of qualified employees has also occurred and despite good faith efforts to do, we have not yet been able to rehire or fully replace staff reductions which were previously furloughed, laid off or retired.

Since the beginning of the COVID-19 pandemic, our Pharmacy business has experienced reduced sales trends in certain areas, increased costs and reduced staff. Many of our primary physician referral sources have been operating at substantially reduced capacity. Until these referral sources are at full capacity, we believe the COVID-19 pandemic will continue to affect the demand for DME products and Retail and Institutional Pharmacy drugs and products. Reductions in employee hours have been made in response to the lower demand. Nursing homes and other customers of such Institutional Pharmacy services are currently being adversely affected by the spreading of the COVID-19 pandemic, and this may be expected to have a further negative effect on such demand. Our Institutional Pharmacy services have experienced increased costs and operational inefficiencies due to measures taken to protect our employees and by access controls and other restrictions implemented by our institutional customers. The impact of the COVID-19 pandemic has negatively affected our supply processes, especially with respect to access to respiratory equipment and certain personal protective equipment and cleaning products. We believe the effect of the COVID–19 pandemic and public and governmental responses to it negatively affected our last three fiscal quarters results.

During the fourth quarter of fiscal 2020, our Healthcare and Pharmacy segments received approximately $4,586,000 and in the first quarter of fiscal 2021 we received $106,000 in general and targeted Provider Relief Fund (“PRF”) distributions. During the fourth quarter of fiscal 2020, we also received $3,234,000 in Paycheck Protection Program (“PPP”) loans, administered by the Small Business Administration (“SBA”). Both the PRF and PPP funds are provided for under the Coronavirus Aid Relief and Economic Security (“CARES”) Act, and we have received a total of $7,926,000 of such funding.

The distributions from the PRF are not subject to repayment provided we are able to attest to and comply with the terms and conditions of the funding, including demonstrating that the funds received have been used for healthcare-related expenses or “Lost Revenues” (as defined by HHS) attributable to COVID-19. Such funds under the PRF are accounted for as government grants and are recognized on a systematic and rational basis once there is reasonable assurance that the applicable terms and conditions required to retain the funds have been met. HHS has released “CARES Act Provider Relief Fund Frequently Asked Questions” (“FAQ”) numerous times since April 3, 2020 through October 28, 2020 to clarify PRF requirements and has provided expansive examples of the reporting requirements in efforts to demonstrate what amounts of the PRF received may be considered to have been earned and may be retained. The Company continues to review and analyze the FAQ which it believes still leaves substantial uncertainty as to the proper use and reporting of PRF funds. We are reporting $31 of PRF in other income in our consolidated statement of operations for our fiscal quarter ended September 30, 2020 for COVID-19 related expenses. The unrecognized amount of the PRF are recorded under the caption “Unearned CARES Act Funds” in our consolidated balance sheets. We will continue to monitor compliance with the terms and conditions of the PRF and the impact of the pandemic on our revenues and expenses. If we are unable to attest to or comply with current or future terms and conditions, and there is no assurance we will be able to do so, our ability to retain some or all of the distributions received may be impacted. We currently believe we may not be able to utilize a portion of the PRF funds received under the currently existing interpretations by HHS and have to return the unutilized funds in the future.

Forgiveness of PPP loans may be available if the loans are used to pay wages, rent, utilities and interest on certain debt during the eight-week period following receipt of the loan proceeds, subject to Federally-established terms and conditions. During July 2020, the allowable period for the use of PPP loan proceeds was amended to allow for a 24-week utilization period. The borrowing subsidiaries must apply for loan forgiveness with the lending bank within ten months after the end of the allowable period. The forgiveness applications are to be reviewed by both the lender and the SBA and a loan forgiveness amount, if any, will be determined. There can be no assurance, however, that any of the PPP loans to us will be forgiven, or if forgiven, the amount of such forgiveness. Loan proceeds not forgiven are payable over two years at a 1% annual interest rate. The two-year loan repayment begins two months after the loan forgiveness amount is determined by SBA. The Company has not yet applied for forgiveness of any of its PPP loans and recorded no income relating to the PPP loans through September 30, 2020.

Going forward, the Company is unable to determine the extent to which the COVID-19 pandemic will continue to affect its assets and operations. Our ability to make estimates of the effect of the COVID-19 pandemic on revenues, expenses or changes in accounting judgments that have had or are reasonably likely to have a material effect on our financial statements is currently limited. The nature and extent of the effect of the COVID-19 pandemic on our balance sheet and results of operations will depend on the severity and length of the pandemic; government actions to mitigate the pandemic’s effect; regulatory changes in response to the pandemic, especially those that affect our hospital, nursing home and pharmacy operations; and existing and potential government assistance that may be provided, including the requirements applicable to PRF receipts and PPP loans.

SunLink Health Systems, Inc. is the parent company of subsidiaries that own and operate healthcare properties and businesses in the Southeast. Each of the Company’s businesses is operated locally with a strategy of linking patients’ needs with healthcare professionals. For additional information on SunLink Health Systems, Inc., please visit the Company’s website.

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements regarding the company’s business strategy. These forward-looking statements are subject to certain risks, uncertainties and other factors, which could cause actual results, performance and achievements to differ materially from those anticipated. Certain of those risks, uncertainties and other factors are disclosed in more detail in the company’s Annual Report on Form 10-K for the year ended June 30, 2020 and other filings with the Securities and Exchange Commission which can be located at www.sec.gov.

 
SUNLINK HEALTH SYSTEMS, INC. ANNOUNCES
FISCAL 2021 FIRST QUARTER RESULTS
Amounts in 000’s, except per share and volume amounts
CONSOLIDATED STATEMENTS OF EARNINGS (LOSS)

Three Months Ended September 30,

 

2020

 

2019

 

 

 

% of Net

 

 

 

% of Net

 

Amount

 

Revenues

 

Amount

 

Revenues

Net Revenues

$

10,422

 

 

100.0

%

$

11,652

 

100.0

%

Costs and Expenses:
Cost of goods sold

 

4,070

 

 

39.1

%

 

4,344

 

37.3

%

Salaries, wages and benefits

 

4,385

 

 

42.1

%

 

4,909

 

42.1

%

Supplies

 

224

 

 

2.1

%

 

319

 

2.7

%

Purchased services

 

647

 

 

6.2

%

 

703

 

6.0

%

Other operating expenses

 

949

 

 

9.1

%

 

1,103

 

9.5

%

Rents and leases

 

170

 

 

1.6

%

 

159

 

1.4

%

Depreciation and amortization

 

300

 

 

2.9

%

 

335

 

2.9

%

Operating Loss

 

(323

)

 

-3.1

%

 

(220

)

-1.9

%

 
Interest Expense – net

 

(7

)

 

-0.1

%

 

(30

)

-0.3

%

Federal stimulus – Pandemic relief funds

 

31

 

 

0.3

%

 

0

 

0.0

%

Gains on sale of assets

 

8

 

 

0.1

%

 

107

 

0.9

%

 
Loss from Continuing Operations before
Income Taxes

 

(291

)

 

-2.8

%

 

(143

)

-1.2

%

Income Tax expense (benefit)

 

0

 

 

0.0

%

 

0

 

0.0

%

Loss from Continuing Operations

 

(291

)

 

-2.8

%

 

(143

)

-1.2

%

Earnings (Loss) from Discontinued Operations, net of tax

 

(49

)

 

-0.5

%

 

(118

)

-1.0

%

Net Loss

$

(340

)

 

-3.3

%

$

(261

)

-2.2

%

Loss Per Share from Continuing Operations:
Basic

$

(0.04

)

$

(0.02

)

Diluted

$

(0.04

)

$

(0.02

)

Earnings (Loss) Per Share from Discontinued Operations:
Basic

$

(0.01

)

$

(0.02

)

Diluted

$

(0.01

)

$

(0.02

)

Net Loss Per Share:
Basic

$

(0.05

)

$

(0.04

)

Diluted

$

(0.05

)

$

(0.04

)

Weighted Average Common Shares Outstanding:
Basic

 

6,899

 

 

6,987

 

Diluted

 

6,899

 

 

6,987

 

 
HEALTHCARE FACILITIES VOLUME STATISTICS
 
Hospital and Nursing Home Admissions

 

66

 

 

122

 

Hospital and Nursing Home Patient Days

 

5,195

 

 

6,961

 

 
SUMMARY BALANCE SHEETS

September 30,

 

June 30,

 

2020

 

 

 

2020

 

ASSETS
Cash and Cash Equivalents

$

11,403

 

$

11,184

 

Accounts Receivable – net

 

4,195

 

 

4,315

 

Other Current Assets

 

4,420

 

 

4,424

 

Property Plant and Equipment, net

 

5,622

 

 

5,324

 

Long-term Assets

 

2,605

 

 

2,724

 

$

28,245

 

$

27,971

 

LIABILITIES AND SHAREHOLDERS’ EQUITY
Accounts Payable

$

1,614

 

$

872

 

Unearned CARES Act Funds

 

4,607

 

 

4,532

 

Other Current Liabilities

 

5,867

 

 

6,012

 

Long-term Debt and Other Noncurrent Liabilities

 

2,754

 

 

2,812

 

Shareholders’ Equity

 

13,403

 

 

13,743

 

$

28,245

 

$

27,971

 

 

Robert M. Thornton, Jr.

Chief Executive Officer

(770) 933-7004

KEYWORDS: Georgia United States North America

INDUSTRY KEYWORDS: Hospitals Health Pharmaceutical Nursing Medical Supplies

MEDIA:

Logo
Logo